Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 1/20 | 0.62 |
| ▸ | ITGB1 | P05556 | 13/20 | 0.36 |
| ▸ | ITGA5 | P08648 | 10/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 4/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.32 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23992520 | 0.92 | ITGAL (0.61) | ITGALITGB1ITGA5ADRB1ADRB3 | |
| SCHEMBL18867996 | 0.90 | ITGAL (0.53) | ITGALITGB1ITGA5ADRB1ADRB3 | |
| SCHEMBL4922611 | 0.88 | ITGAL (0.62) | ITGALITGB1ITGA5ADRB1ADRB3 | |
| SCHEMBL12054488 | 0.88 | ITGAL (0.62) | ITGALITGB1ITGA5ADRB1ADRB3 | |
| SCHEMBL19157561 | 0.88 | ITGAL (0.62) | ITGALITGB1ITGA5ADRB1ADRB3 | |
| SCHEMBL18881151 | 0.88 | ITGAL (0.56) | ITGALITGB1ITGA5ADRB1ADRB3 | |
| SCHEMBL23153582 | 0.87 | ITGAL (0.60) | ITGALITGB1ITGA5ADRB1ADRB3 | |
| SCHEMBL18883515 | 0.84 | ITGAL (0.61) | ITGALITGB1ITGA5ADRB1ADRB3 | |
| SCHEMBL18885225 | 0.84 | ITGAL (0.61) | ITGALITGB1ITGA5ADRB1ADRB3 | |
| SCHEMBL16307471 | 0.84 | ITGAL (0.57) | ITGALITGB1ITGA5ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3797775-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | Novartis AG (CH) | 2021-03-31 | — | — | EP | disclosed |
| US-10960087-B2 | Compositions and methods for treatment of diabetic retinopathy | NOVARTIS AG (CH) | 2021-03-30 | — | — | US | disclosed |
| EP-3167886-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA | SARcode Bioscience Inc. (US) | 2017-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10960087-B2 | Compositions and methods for treatment of diabetic retinopathy | VCAM1, ITGB1, ICAM1 | ITGAL 5/4885ITGB1 2/4885ITGA5 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.